Verastem, Inc.
VSTM
Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylate MEK. The company also engages in developing RAMP 20ā¦ read more
Healthcare
Biotechnology
13 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$8.07
Price+1.77%
$0.14
1Y
Price
Market Cap
$488.545m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-1197.7%
EBITDA Margin-1213.6%
Net Profit Margin-1528.4%
Free Cash Flow MarginRevenue
-$7.839m
-178.4%
1y CAGR-92.8%
3y CAGR+12.5%
5y CAGREarnings
-$166.555m
-27.5%
1y CAGR-31.8%
3y CAGR-24.8%
5y CAGREPS
-$4.17
-13.9%
1y CAGR+2.4%
3y CAGR+3.4%
5y CAGRBook Value
$36.056m
$196.264m
Assets$160.208m
Liabilities$75.318m
DebtDebt to Assets
38.4%
-0.5x
Debt to EBITDAFree Cash Flow
-$120.233m
-14.7%
1y CAGR-23.9%
3y CAGR-22.6%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company